SCHEMBL4164829

SCHEMBL4164829

COCCN1C(=O)C2(NC(=O)NC2=O)c2cc(C)ccc21

nearest known ligand 0.41

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ AKR1B1 P15121 2/20 0.41
▸ PTGDR2 Q9Y5Y4 1/20 0.36
▸ SMN1; SMN2 Q16637 3/20 0.35
▸ ALDH1A1 P00352 6/20 0.35
▸ LMNA P02545 4/20 0.35
▸ MAPT P10636 4/20 0.35
▸ POLB P06746 2/20 0.34
▸ MEN1 O00255 1/20 0.34
▸ KMT2A Q03164 1/20 0.34
▸ TDP1 Q9NUW8 1/20 0.34
▸ RCE1 Q9Y256 1/20 0.34
▸ L3MBTL1 Q9Y468 1/20 0.34
▸ MAPK1 P28482 1/20 0.34
▸ BACE1 P56817 2/20 0.33
▸ PKM P14618 1/20 0.33
▸ CNR1 P21554 1/20 0.33
▸ GPR55 Q9Y2T6 1/20 0.33
▸ ADAMTS5 Q9UNA0 1/20 0.33
▸ THRB P10828 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4170928 0.93 AKR1B1 (0.39) AKR1B1SMN1; SMN2ALDH1A1LMNAMAPT
SCHEMBL4171124 0.88 AKR1B1 (0.39) AKR1B1SMN1; SMN2ALDH1A1LMNAMAPT
SCHEMBL4164837 0.87 AKR1B1 (0.48) AKR1B1PTGDR2MAPTPOLB
SCHEMBL4167292 0.87 PTGDR2 (0.49) AKR1B1PTGDR2ALDH1A1LMNAMAPT
SCHEMBL4170549 0.85 ALDH1A1 (0.52) SMN1; SMN2ALDH1A1LMNAMAPTPOLB
SCHEMBL4169530 0.85 L3MBTL1 (0.42) SMN1; SMN2ALDH1A1LMNAMAPTPOLB
SCHEMBL4163278 0.84 AKR1B1 (0.44) AKR1B1SMN1; SMN2ALDH1A1LMNAMAPT
SCHEMBL4159430 0.84 PLA2G7 (0.50) AKR1B1SMN1; SMN2ALDH1A1LMNAMAPT
SCHEMBL4255427 0.83 MAPT (0.45) AKR1B1SMN1; SMN2ALDH1A1LMNAMAPT
SCHEMBL4254388 0.83 AKR1B1 (0.41) AKR1B1SMN1; SMN2ALDH1A1LMNAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090076049-A1 Novel Spiro [Imidazolidine-4, 3' -Indole] 2, 2', 5' (1H) Triones for Treatment of Conditions Associated with Vanilloid Receptor 1 ASTRAZENECA AB (SE) 2009-03-19 — — US claimed
US-20090076049-A1 Novel Spiro [Imidazolidine-4, 3' -Indole] 2, 2', 5' (1H) Triones for Treatment of Conditions Associated with Vanilloid Receptor 1 ASTRAZENECA AB (SE) 2009-03-19 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090076049-A1 Novel Spiro [Imidazolidine-4, 3' -Indole] 2, 2', 5' (1H) Triones for Treatment of Conditions Associated with Vanilloid Receptor 1 TRPV1, TRPV5, TRPV2 AKR1B1 344/4885PTGDR2 172/4885SMN1; SMN2 2877/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback